AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SKILLING2.7.2020 15:09:08 CEST | Press release
Skilling Launches MT4
CA-ZYNGA2.7.2020 15:07:08 CEST | Press release
Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast
SMITHS-DETECTION2.7.2020 11:02:07 CEST | Press release
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT
EUSA-PHARMA2.7.2020 10:02:10 CEST | Press release
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
DEENOVA2.7.2020 09:36:08 CEST | Press release
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries
ADVA2.7.2020 09:02:06 CEST | Press release
Telstra Wholesale deploys ADVA technology in Australian-first Ethernet service
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom